DDInter537 DDInter899
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Diclofenac {u} (Compound) resembles {v} (Compound) Clonidine
Diclofenac {u} (Compound) resembles {v} (Compound) Nepafenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromfenac
Diclofenac {u} (Compound) binds {v} (Gene) ALOX5
Diclofenac {u} (Compound) palliates {v} (Disease) systemic scleroderma
Diclofenac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Diclofenac {u} (Compound) downregulates {v} (Gene) PUF60
Diclofenac {u} (Compound) causes {v} (Side Effect) Corneal disorder
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Colestipol
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Diclofenac (Compound) resembles Clonidine (Compound)
Diclofenac (Compound) resembles Nepafenac (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Diclofenac (Compound) binds ALOX5 (Gene)
Diclofenac (Compound) palliates systemic scleroderma (Disease)
Diclofenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Diclofenac (Compound) downregulates PUF60 (Gene)
Diclofenac (Compound) causes Corneal disorder (Side Effect)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Colestipol
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine